Nevro’s Senza Omnia SCS platform receives CE mark approval. Credit: Nevro Corp.

Nevro has received CE mark approval for the Senza Omnia spinal cord stimulation (SCS) system for the treatment of chronic pain.

The system provides the company’s proprietary HF10 therapy along with other available frequencies between 2Hz-10,000Hz. Other SCS systems on the market are limited to frequencies below 1,200Hz.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Due to its ability to pair frequencies, Omnia can pair HF10 with other waveforms such as traditional, paresthesia-based stimulation, subthreshold 1kHz therapy or burst waveforms.

The Omina SCS platform consists of a new programmer, which enables physicians to offer a range of waveforms across the full frequency spectrum, either separately or paired together with HF10.

It also includes a redesigned patient remote, enabling better programming capacity, and allows for the flexibility to expand on the HF10 algorithm.

Additionally, an updated and upgradeable implantable pulse generator and a redesigned slimmer patient charger with an improved user interface are part of the new SCS system.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nevro chairman, CEO and president Keith Grossman said: “Following a successful launch in the United States late last year, we are excited to now have approval for the Senza Omnia SCS system in Europe.

“As conditions in the marketplace allow, we will be introducing Omnia to physicians throughout Europe. This next-generation SCS system has been developed in close consultation with customers and is designed to provide a comprehensive solution to manage chronic pain.”

Last year, Nevro launched Senza Omnia SCS system in the US, following its regulatory approval by the US Food and Drug Administration (FDA).